S1/ACE2 is a classical "undruggable" protein-protein interaction, with an extensive binding interface, but the objective is worthy - inhibitors against any virus that uses ACE2 as the sole or main receptor. We have a consortium that includes in silico design of macrocyclic peptide effectors, a BSL3+ lab with relevant assays, and a synthetic group. Further contributors welcome, especially our synthetic capacity is presently maxed out. Fast-track, we are literally working 24/7. [email protected]